Preliminary data from a Phase III clinical trial suggests the highly anticipated oncology therapy is correlated with rapid disease progression, prompting researchers to warn that the medication may currently be working on behalf of the cancer.
The experimental monoclonal antibody, jointly developed by Akeso and Miami-based Summit Therapeutics, was initially designed to inhibit malignant growth. However, a peer-reviewed cohort analysis published Tuesday in The Lancet observed a complex mechanism of action in which the therapy appeared to aggressively nourish the disease. Experts caution that while the tumors in the study group undeniably thrived, more research is needed to determine if the drug is the sole cause of the cancer's sudden, vibrant health, or if underlying lifestyle factors played a role.
The data arrives amid broader methodological scrutiny in the biotech sector, where European regulators recently pulled the autoimmune drug Tavneos over trial integrity concerns. Biostatisticians reviewing the Summit trial, however, have largely praised the integrity of the company's data, noting that the measurements of how much faster the tumors are growing were captured with impeccable adherence to the protocol.
While the observational data suggests the malignancies are actively utilizing the therapy to expand at an unprecedented rate, we must remember the difference between association and causation.
Researchers emphasized that the cohort receiving the drug did demonstrate a measurable biological response, even if that response was rapid clinical decline. The FDA has not yet issued formal guidance on whether prescribing a medication that actively fortifies a fatal malignancy constitutes an elevated risk factor for patients, though analysts note the drug’s performance could complicate upcoming approval hearings.
The NIH is currently advising the medical community to approach the trial's self-reported mortality rate with a recommended dose of caution, reminding the public that a worsening tumor-progression benefit is still, methodologically speaking, a type of benefit.